2型糖尿病合并代谢相关脂肪性肝病患者的TG/HDL-C与肝脏脂肪变相关性研究
Study on the Correlation of TG/HDL-C with Hepatic Steatosis in Patients with Type 2 Diabetes Mellitus Combined with Metabolism-Related Fatty Liver Disease
DOI: 10.12677/acm.2025.152539, PDF,   
作者: 崔亚迪:河北医科大学研究生学院,河北 石家庄;张冬雨:徐州医科大学研究生学院,江苏 徐州;吴 韬*:石家庄市人民医院内分泌科,河北 石家庄
关键词: 2型糖尿病代谢相关脂肪性肝病TG/HDL-CType 2 Diabetes Mellitus Metabolism-Related Fatty Liver Disease TG/HDL-C
摘要: 目的:探究2型糖尿病(T2DM)合并代谢相关脂肪性肝病(MAFLD)患者的TG/HDL-C与肝脏脂肪变相关性。方法:选取2023年9月至2024年8月于石家庄市人民医院内分泌科住院接受治疗27~75岁T2DM合并MAFLD患者共186例。根据代表肝脏脂肪变性的严重程度的受控衰减参数(CAP)水平(S0: CAP < 238 dB/m, S1: 238 dB/m ≤ CAP < 260 dB/m, S2: 260 dB/m ≤ CAP < 292 dB/m, S3: CAP ≥ 292 dB/m)将患者分为非重度肝脏脂肪变组80例和重度肝脏脂肪变组106例,所有受试者均测量甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、TG/HDL-C、谷丙转氨酶(ALT)、谷草转氨酶(AST)、体质量指数(BMI)、瞬时弹性成像参数CAP值(dB/m)等指标。结果:(1) 重度脂肪变组BMI、FPG、FINS、FCP、HOMA-IR、HbA1c、TC、TG、LDL-C、ALT、AST、γ-GGT、TG/HDL-C、CAP均高于非重度脂肪变组,差异均有统计学意义(P < 0.05)。(2) 对各指标行Pearson/Spearman相关性分析显示,CAP与FINS、FCP、HOMA-IR、TG、ALT、AST、γ-GGT、BMI、TG/HDL-C等均呈正相关(r值分别为0.407、0.392、0.422、0.547、0.381、0.433、0.368、0.538、0.568)。(3) 行二元Logistic多因素回归分析得出:TG/HDL-C、LDL-C、BMI、ALT是T2DM合并MAFLD患者肝脏脂肪变的独立危险因素(TG/HDL-C 95%置信区间1.726 (1.238, 2.407),P = 0.001)。(4) 将TG/HDL-C、TG、LDL-C、ALT代入ROC曲线分析,曲线下面积分别为:0.753、0.747、0.609、0.695。其中TG/HDL-C敏感度54.7%,特异度86.3%,TG、TG/HDL-C均能预测T2DM合并MAFLD患者的重度肝脏脂肪变性,但TG/HDL-C预测价值更优(P = 0.000),具有统计学意义。
Abstract: Objective: To investigate the correlation between TG/HDL-C and hepatic steatosis in patients with type 2 diabetes mellitus (T2DM) combined with metabolism-associated fatty liver disease (MAFLD). Methods: A total of 186 patients with T2DM combined with MAFLD aged 27-75 years who were hospitalized in the Department of Endocrinology of Shijiazhuang People’s Hospital from September 2023 to August 2024 were selected. The patients were categorized into 80 cases in the non-severe hepatic steatosis group and 106 cases in the severe hepatic steatosis group according to the level of controlled attenuation parameter (CAP), which represents the severity of hepatic steatosis (S0: CAP < 238 dB/m, S1: 238 dB/m ≤ CAP < 260 dB/m, S2: 260 dB/m ≤ CAP < 292 dB/m, and S3: CAP ≥ 292 dB/m). The steatosis group consisted of 106 cases, and triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), TG/HDL-C, alanine aminotransferase (ALT), alanine transaminase (AST), body mass index (BMI), and CAP value of transient elastography parameter (dB/m) were measured in all the subjects. Results: (1) BMI, FPG, FINS, FCP, HOMA-IR, HbA1c, TC, TG, LDL-C, ALT, AST, γ-GGT, TG/HDL-C, and CAP were higher in the severe steatosis group than those in the non-severe steatosis group, and the differences were statistically significant (P < 0.05). (2) The correlation analyses of each index showed that the Pearson/Spearman correlation analysis showed that the BMI, body mass index (AST), transient elastography parameter CAP value (dB/m), and other indexes were higher. Spearman correlation analysis showed that CAP was positively correlated with FINS, FCP, HOMA-IR, TG, ALT, AST, γ-GGT, BMI, and TG/HDL-C (r-values of 0.407, 0.392, 0.422, 0.547, 0.381, 0.433, 0.368, 0.538, respectively, 0.568). (3) Binary logistic multifactorial regression analysis was performed to conclude that TG/HDL-C, LDL-C, BMI, and ALT were independent risk factors for hepatic steatosis in patients with T2DM combined with MAFLD (TG/HDL-C 95% confidence interval 1.726 (1.238, 2.407), P = 0.001). (4) Substituting TG/HDL-C, TG, LDL-C, and ALT into the ROC curve analysis, the areas under the curve were 0.753, 0.747, 0.609, and 0.695, respectively of which the sensitivity of TG/HDL-C was 54.7% and specificity 86.3%, both TG and TG/HDL-C could predict severe hepatic steatosis in patients with T2DM combined with MAFLD, but the predictive value of TG/HDL-C was superior (P = 0.000), which was statistically significant.
文章引用:崔亚迪, 张冬雨, 吴韬. 2型糖尿病合并代谢相关脂肪性肝病患者的TG/HDL-C与肝脏脂肪变相关性研究[J]. 临床医学进展, 2025, 15(2): 1799-1807. https://doi.org/10.12677/acm.2025.152539

参考文献

[1] Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., et al. (2020) NAFLD and Cardiovascular Diseases: A Clinical Review. Clinical Research in Cardiology, 110, 921-937. [Google Scholar] [CrossRef] [PubMed]
[2] Tanase, D.M., Gosav, E.M., Costea, C.F., Ciocoiu, M., Lacatusu, C.M., Maranduca, M.A., et al. (2020) The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Diabetes Research, 2020, Article ID: 3920196. [Google Scholar] [CrossRef] [PubMed]
[3] Sohrabi, Y., Reinecke, H. and Godfrey, R. (2021) Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in Covid-19. Trends in Endocrinology & Metabolism, 32, 132-134. [Google Scholar] [CrossRef] [PubMed]
[4] Li, X., Hu, X., Pan, T., Dong, L., Ding, L., Wang, Z., et al. (2021) Kanglexin, a New Anthraquinone Compound, Attenuates Lipid Accumulation by Activating the AMPK/SREBP-2/PCSK9/LDLR Signalling Pathway. Biomedicine & Pharmacotherapy, 133, Article ID: 110802. [Google Scholar] [CrossRef] [PubMed]
[5] Xue, L., Qi, H., Zhang, H., Ding, L., Huang, Q., Zhao, D., et al. (2020) Targeting Srebp-2-Regulated Mevalonate Metabolism for Cancer Therapy. Frontiers in Oncology, 10, Article No. 1510. [Google Scholar] [CrossRef] [PubMed]
[6] Lee, W., Ahn, J.H., Park, H.H., Kim, H.N., Kim, H., Yoo, Y., et al. (2020) Covid-19-Activated SREBP2 Disturbs Cholesterol Biosynthesis and Leads to Cytokine Storm. Signal Transduction and Targeted Therapy, 5, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[7] Lu, J., Meng, Z., Cheng, B., Liu, M., Tao, S. and Guan, S. (2019) Apigenin Reduces the Excessive Accumulation of Lipids Induced by Palmitic Acid via the AMPK Signaling Pathway in Hepg2 Cells. Experimental and Therapeutic Medicine, 18, 2965-2971. [Google Scholar] [CrossRef] [PubMed]
[8] Liu, X., Wu, Q., Chen, Z., Yan, G., Lu, Y., Dai, H., et al. (2020) Elevated Triglyceride to High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio Increased Risk of Hyperuricemia: A 4-Year Cohort Study in China. Endocrine, 68, 71-80. [Google Scholar] [CrossRef] [PubMed]
[9] Baez-Duarte, B.G., Zamora-Gínez, I., González-Duarte, R., et al. (2017) Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Index as a Reference Criterion of Risk for Metabolic Syndrome (MetS) and Low Insulin Sensitivity in Apparently Healthy Subjects. Gaceta Médica de México, 153, 152-158.
[10] Chen, Z., Hu, H., Chen, M., Luo, X., Yao, W., Liang, Q., et al. (2020) Association of Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Incident of Diabetes Mellitus: A Secondary Retrospective Analysis Based on a Chinese Cohort Study. Lipids in Health and Disease, 19, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[11] Fan, N., Peng, L., Xia, Z., Zhang, L., Song, Z., Wang, Y., et al. (2019) Triglycerides to High-Density Lipoprotein Cholesterol Ratio as a Surrogate for Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Lipids in Health and Disease, 18, Article No. 39. [Google Scholar] [CrossRef] [PubMed]
[12] Xue, J., Wang, Y., Li, B., Yu, S., Wang, A., Wang, W., et al. (2021) Triglycerides to High-Density Lipoprotein Cholesterol Ratio Is Superior to Triglycerides and Other Lipid Ratios as an Indicator of Increased Urinary Albumin-to-Creatinine Ratio in the General Population of China: A Cross-Sectional Study. Lipids in Health and Disease, 20, Article No. 13. [Google Scholar] [CrossRef] [PubMed]
[13] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) (上) [J]. 中国实用内科杂志, 2021, 41(8): 668-695.
[14] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024 年版) [J]. 中华肝脏病杂志, 2024, 32(5): 418-434.
[15] 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227.
[16] 孙先丽, 叶玲玲, 孙红娟. 腰高比预测非酒精性脂肪肝的前瞻性研究[J]. 海南医学, 2022, 33(10): 1245-1248.
[17] Vallejo-Vaz, A.J., Corral, P., Schreier, L. and Ray, K.K. (2020) Triglycerides and Residual Risk. Current Opinion in Endocrinology, Diabetes & Obesity, 27, 95-103. [Google Scholar] [CrossRef] [PubMed]
[18] Chapman, M.J., et al. (2011) Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. European Heart Journal, 32, 1345-1361.
[19] Oliveros-Montiel, A., Santos-López, G. and Sedeño-Monge, V. (2020) Proteins Involved in Lipid Metabolism as Possible Biomarkers or Predisposing Factors for Non-Alcoholic Fatty Liver Disease. Acta Gastro-Enterologica Belgica, 83, 622-630.
[20] Busik, J.V. (2021) Lipid Metabolism Dysregulation in Diabetic Retinopathy. Journal of Lipid Research, 62, Article ID: 100017. [Google Scholar] [CrossRef] [PubMed]
[21] Charles, K.N., Shackelford, J.E., Faust, P.L., Fliesler, S.J., Stangl, H. and Kovacs, W.J. (2020) Functional Peroxisomes Are Essential for Efficient Cholesterol Sensing and Synthesis. Frontiers in Cell and Developmental Biology, 8, Article ID: 560266. [Google Scholar] [CrossRef] [PubMed]
[22] Mato, J.M., Alonso, C., Noureddin, M. and Lu, S.C. (2019) Biomarkers and Subtypes of Deranged Lipid Metabolism in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 25, 3009-3020. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, Y., Zhang, W., Wu, X., Wu, J., Sun, C., Luo, F., et al. (2021) Systemic Overexpression of GDF5 in Adipocytes but Not Hepatocytes Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice. Canadian Journal of Gastroenterology and Hepatology, 2021, Article ID: 8894685. [Google Scholar] [CrossRef] [PubMed]
[24] Chao, H., Chao, S., Lin, H., Ku, H. and Cheng, C. (2019) Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 20, Article No. 298. [Google Scholar] [CrossRef] [PubMed]
[25] Luo, N., Yang, C., Zhu, Y., Chen, Q. and Zhang, B. (2021) Diosmetin Ameliorates Nonalcoholic Steatohepatitis through Modulating Lipogenesis and Inflammatory Response in a Stat1/Cxcl10-Dependent Manner. Journal of Agricultural and Food Chemistry, 69, 655-667. [Google Scholar] [CrossRef] [PubMed]
[26] Tan, X., Liu, Y., Long, J., Chen, S., Liao, G., Wu, S., et al. (2019) Trimethylamine n‐Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. Molecular Nutrition & Food Research, 63, e1900257. [Google Scholar] [CrossRef] [PubMed]